Claya review

Claya gets the hardest part right and the easiest part wrong. The hard part is the structure: one figure per molecule, medication and clinical review and shipping inside it, no membership underneath, an explicit promise that the price does not move with the dose, and a safety notice stating plainly that compounded products are regulated by state boards and not evaluated by the FDA. A flat-dose promise made on the product card rather than in a banner is the stronger form of that claim, and for a reader who expects to titrate upward it is genuinely reassuring. For a reader who intends to stay small it is the opposite, and worth naming: at a quarter dose you pay the full figure for a fraction of the drug, and the company tells you so in advance. The easy part it gets wrong is arithmetic. The card is headed as a monthly plan and priced by the month, and one bullet down it says shipments arrive every four weeks — which is thirteen of them in a year, not twelve. Anyone budgeting a year from the monthly label will be short by about one shipment. And the semaglutide figure moves depending on where you look: the plan card and the product page disagree by thirty dollars in a single visit, which makes the cheaper of the two an advertisement rather than a rate.

Vs median

$20/mo below the $169 median across the 242 of 373 programs we track that publish a plain monthly rate

Market

$59–$1300/mo is the full published spread in our ranking

Structure

Same price at every dose

Consult

Included in the price

Dietitian

Not included

Labs

Not required

Pricing

Flat at every dose

Price last updated

August 2026

Claya does not publicly identify the pharmacy that fills its prescriptions. No bloodwork is required before you start. A clinician review is included in the price.

Claya gets the hardest part right and the easiest part wrong. The hard part is the structure: one figure per molecule, medication and clinical review and shipping inside it, no membership underneath, an explicit promise that the price does not move with the dose, and a safety notice that states plainly that compounded products are regulated by state boards and not evaluated by the FDA. A flat-dose promise made on the product card rather than in a banner is the stronger form of that claim, and for a reader who expects to titrate upward it is genuinely reassuring. For a reader who intends to stay small it is the opposite, and worth naming: at a quarter dose you are paying the full figure for a fraction of the drug, and the company is telling you so in advance. The easy part it gets wrong is arithmetic. The card is headed as a monthly plan and priced by the month, and one bullet down it says shipments arrive every four weeks — which is thirteen of them in a year, not twelve. Anyone budgeting a year from the monthly label will be short by about one shipment. And the semaglutide figure moves depending on where you look: the plan card and the product page disagree by thirty dollars in a single visit, which makes the cheaper of the two an advertisement rather than a rate.

Shipments arrive every four weeks against a price labeled monthly, so a year takes thirteen.

• The semaglutide figure differs by thirty dollars between the plan card and the product page.
• A flat price means a quarter dose costs what a full dose costs.

Claya is one of 373 low-dose GLP-1 programs we track, and 242 of them publish a monthly rate you can read before signing up. The ranking lists every published price on one screen, ordered with the companies that pay us first — a mechanism we state there, on the page it applies to.

Intentional GLP-1 microdosing is off-label and unproven — no randomized trial has established that a sub-label dose does anything, and any dose belongs with a clinician who knows your history. If you are going to have that conversation, have it with real numbers.

• What microdosing GLP-1 costs
• Low dose vs full dose
• Microdosing semaglutide
• The true annual cost of a plan
• What a flat price costs at a low dose